GSK and Merck KGaA entered a global alliance to co-develop bintrafusp alfa (M7824), a bifunctional TGF-beta trap/anti-PD-L1 fusion protein. Deal terminated in 2021 after clinical failures.
Key facts
AnnouncedFeb 05, 2019
ClosedFeb 05, 2019
Deal value$4.2B
Deal typeCo-Development
Therapeutic areaOncology
IndicationsNSCLC, Multiple solid tumors
Key assetsbintrafusp alfa (M7824)
MechanismTGF-beta trap / anti-PD-L1 bifunctional fusion protein